Journal of Neuroscience Nursing · 4 Nov 2026
Asundexian in Stroke: Nursing Pharmacology Update
Fnu Alfandyh-index 1, Dennis K. Constan
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
- Europe PMC0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
BACKGROUND: Patients remain at increased risk of recurrent stroke despite guideline-directed antithrombotic therapy, and antithrombotic escalation strategies are limited by bleeding risk. Asundexian is an emerging therapy that targets factor XIa (FXIa) inhibition without impairing primary hemostasis, thereby reducing pathological thrombosis while mitigating bleeding. This paper aims to provide clinicians with an evidence-based overview of asundexian, an investigational FXIa inhibitor. METHODS: Selected peer-reviewed articles, including available phase 1 to 3 trials, were reviewed and synthesized to present the latest asundexian evidence relevant to stroke prevention. RESULTS: Asundexian 50 mg once daily, when added to antiplatelet therapy, reduced recurrent stroke in the atherosclerotic, non-cardioembolic stroke population, but was inferior to standard-dose apixaban in patients with atrial fibrillation (AF). The hemostasis-sparing profile of asundexian was consistent across populations, supporting the add-on use with antiplatelet therapy. The pharmacologic data of asundexian demonstrate a low-complexity administration profile with near-complete oral bioavailability, <15% renal elimination, a 16- to 18-hour half-life supporting once-daily dosing, crushable tablets, no food or gastric pH effect, and no routine drug-level monitoring. Two safety boundaries include the absence of a specific reversal agent and the need to switch to a direct oral anticoagulant if AF is detected. CONCLUSION: FXIa inhibitors like asundexian are an emerging antithrombotic class that holds the potential to change the paradigm of secondary stroke prevention in non-cardioembolic stroke patients. Optimizing FXIa inhibitor benefits depends on identifying the stroke mechanism, diagnosing AF, and maintaining bleeding surveillance or management without a reversal agent. This update provides an evidence-based overview of asundexian, an oral selective FXIa inhibitor. It summarizes its pharmacologic profile, key clinical evidence, and practice implications for nurses and advanced practice providers caring for stroke patients, as this agent may soon enter clinical practice. Asundexian is not currently available outside clinical trials and remains under regulatory review for clinical use in stroke prevention.
What the data shows
- No database records a citation yet, as is usual for a paper this new.
- Fnu Alfandy has the highest h-index among the authors (1).
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (22)
What it cites, from open citation data, with Crossref's record of each.
Sign in to see 2 more references
A free account opens the rest of the citing papers and references on every paper’s page.